Martingale Asset Management L P Has $510,000 Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Martingale Asset Management L P cut its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 56.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,520 shares of the biopharmaceutical company's stock after selling 19,773 shares during the period. Martingale Asset Management L P's holdings in Agios Pharmaceuticals were worth $510,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Capula Management Ltd bought a new position in Agios Pharmaceuticals in the 4th quarter worth approximately $685,000. Federated Hermes Inc. increased its position in Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after acquiring an additional 582 shares during the period. Envestnet Asset Management Inc. raised its stake in Agios Pharmaceuticals by 3.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after purchasing an additional 795 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Agios Pharmaceuticals by 184.9% in the 4th quarter. Wells Fargo & Company MN now owns 34,808 shares of the biopharmaceutical company's stock valued at $1,144,000 after purchasing an additional 75,800 shares during the period. Finally, Trexquant Investment LP grew its position in Agios Pharmaceuticals by 180.3% in the 4th quarter. Trexquant Investment LP now owns 69,971 shares of the biopharmaceutical company's stock worth $2,299,000 after purchasing an additional 45,005 shares during the last quarter.

Remove Ads

Agios Pharmaceuticals Trading Up 1.1 %

Agios Pharmaceuticals stock traded up $0.30 during mid-day trading on Tuesday, hitting $27.82. The stock had a trading volume of 607,625 shares, compared to its average volume of 710,601. The stock has a 50-day simple moving average of $31.12 and a two-hundred day simple moving average of $38.98. The stock has a market capitalization of $1.59 billion, a PE ratio of 2.45 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

AGIO has been the subject of several recent research reports. StockNews.com cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price target for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $56.57.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.